Engineered iPSCs for HLA-Independent Gamma-Delta T Cell Generation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating γδ T cells for allogeneic cell therapy are limited by the need for specific HLA matching and the risk of graft-versus-host disease, as well as inefficiencies in expanding and differentiating T cells.

Innovation Solution

The development of genetically engineered induced pluripotent stem cells (iPSCs) expressing a rearranged γδ T cell receptor (TCR) and a chimeric antigen receptor (CAR), allowing for the differentiation of iPSCs into γδ T cells capable of recognizing and killing malignant cancer cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional T cell generation methods are used for allogeneic cell therapy, then HLA matching is required, but this increases the complexity of patient screening and treatment customization

Engineering Contradiction:

ImproveHLA matching requirementVSAvoidpatient screening and treatment customization

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent uses γδ T cells that recognize invariant ligands rather than variable HLA molecules, making the therapy universally applicable to all patients regardless of HLA type. The engineered iPSCs produce γδ T cells with broad reactivity to phosphoantigens and stress-induced ligands, eliminating the need for personalized HLA matching while maintaining therapeutic efficacy

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Productivity

If conventional T cell expansion methods are used, then the process is time-consuming and inefficient, but improving expansion efficiency may increase the risk of graft-versus-host disease

Engineering Contradiction:

ImproveT cell expansion efficiencyVSAvoidgraft-versus-host disease risk

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent employs specific culture conditions including IL-2 and IL-15 cytokines, phosphoantigen stimulation (such as HMBPP or zoledronic acid), and controlled oxygen tension to optimize γδ T cell expansion. These parameter changes enable rapid proliferation of γδ T cells with low GVHD risk due to their innate-like properties and lack of dependency on classical HLA molecules

Inventive Principle:

Principle #35Parameter changes

3Reliability

If γδ T cells are engineered with CAR for enhanced cancer recognition, then the ability to kill malignant cells is improved, but the complexity of genetic engineering increases

Engineering Contradiction:

Improvecancer cell recognition and killing abilityVSAvoidgenetic engineering complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines γδ TCR and CAR expressions in the same engineered iPSCs, creating dual-functional γδ CAR-T cells. The iPSCs are genetically modified to express both the γδ TCR (providing innate-like recognition) and the CAR (providing targeted antigen recognition). This merging of functions in a single cell type enhances cancer cell killing ability while using the iPSC platform to streamline the genetic engineering process

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20250066728A1Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem Cells

Publication Date: 2025.02.27 CENTURY THERAPEUTICS INC

AI summary

Provided are methods for generating γδ T cells from induced pluripotent stem cells. Also provided are genetically engineered iPSCs, γδ T cells, CAR-γδ T cells, and methods of using the same.